CJC-1295 is a high-purity, COA-verified research peptide supplied as a lyophilised powder for laboratory research applications. This modified growth hormone–releasing hormone (GHRH) analogue is designed to exhibit extended activity through the inclusion of a Drug Affinity Complex (DAC). Unlike its DAC counterpart, regular CJC1295 has a shorter half-life, allowing for more flexible research protocols and dosing schedules
CJC-1295 has been widely studied in research settings for its role in growth hormone signalling and endocrine regulation pathways.
What CJC-1295 with DAC Is Studied For
In laboratory and preclinical research environments, CJC-1295 with DAC has been investigated for its involvement in:
Stimulation of growth hormone release pathways
Prolonged growth hormone signalling due to extended peptide half-life
Regulation of insulin-like growth factor (IGF-1) production models
Endocrine system signalling and feedback mechanisms
Age-related and metabolic research models
These findings relate to research contexts only and do not imply therapeutic or approved medical use.
Product Details
Form: Lyophilised powder
Purity: ≥ 99% (HPLC verified)
Verification: Certificate of Analysis (COA) provided
Structure: GHRH analogue with Drug Affinity Complex (DAC)
Grade: Research use only
Storage & Handling
Store at 2–8°C or as specified on the COA
Protect from light and moisture
Avoid repeated freeze–thaw cycles
Handle using standard laboratory safety and aseptic techniques
Important Notice
This product is supplied strictly for laboratory research purposes.
Not for human or veterinary use.
Not intended to diagnose, treat, cure, or prevent any disease.
CJC-1295 is a high-purity, COA-verified research peptide supplied as a lyophilised powder for laboratory research applications. This modified growth hormone–releasing hormone (GHRH) analogue is designed to exhibit extended activity through the inclusion of a Drug Affinity Complex (DAC). Unlike its DAC counterpart, regular CJC1295 has a shorter half-life, allowing for more flexible research protocols and dosing schedules
CJC-1295 has been widely studied in research settings for its role in growth hormone signalling and endocrine regulation pathways.
What CJC-1295 with DAC Is Studied For
In laboratory and preclinical research environments, CJC-1295 with DAC has been investigated for its involvement in:
Stimulation of growth hormone release pathways
Prolonged growth hormone signalling due to extended peptide half-life
Regulation of insulin-like growth factor (IGF-1) production models
Endocrine system signalling and feedback mechanisms
Age-related and metabolic research models
These findings relate to research contexts only and do not imply therapeutic or approved medical use.
Product Details
Form: Lyophilised powder
Purity: ≥ 99% (HPLC verified)
Verification: Certificate of Analysis (COA) provided
Structure: GHRH analogue with Drug Affinity Complex (DAC)
Grade: Research use only
Storage & Handling
Store at 2–8°C or as specified on the COA
Protect from light and moisture
Avoid repeated freeze–thaw cycles
Handle using standard laboratory safety and aseptic techniques
Important Notice
This product is supplied strictly for laboratory research purposes.
Not for human or veterinary use.
Not intended to diagnose, treat, cure, or prevent any disease.